Precautions and warnings

People with liver disease risk factors (especially women, those who are overweight, pregnant, or exposed for a long time) should be monitored carefully. Stop treatment if there are any signs or lab results suggesting lactic acidosis or liver damage. Pause the medication if muscle problems (myopathy) are suspected, and stop it completely if myopathy is confirmed. Keep checking liver function tests (LFTs) for several months after stopping treatment, as there is a risk of sudden, severe worsening of hepatitis B. Take extra care if the patient has kidney problems. The safety and effectiveness of this treatment in these patients are not yet known.

Drug Interactions

When used together with peginterferon alfa-2a, there is a higher chance of developing peripheral neuropathy.

Mode of actions

Telbivudine is a man-made medicine similar to the natural substance thymidine. After entering the body, it is changed inside cells into its active form, called telbivudine triphosphate. This active form works by blocking an enzyme (DNA polymerase) that the hepatitis B virus needs to make more of its DNA. By stopping this enzyme, telbivudine helps reduce the virus’s ability to multiply. It is used to treat long-term (chronic) hepatitis B infections.

Dosage & Administration

Oral
Chronic hepatitis B
Adult: 600 mg once daily.
Child: >16 yr: 600 mg once daily.

Renal impairment: Haemodialysis: Administer dose after dialysis session.
CrCl (ml/min)
30-49 600 mg every 48 hr.

Pregnancy & Lactation

Although animal reproduction studies have shown an adverse effect even sometimes unable to demonstrate the risk on the fetus and there are no adequate and well-controlled studies in pregnant women, but during pregnancy, this medicine can be used just when definitely required.

Discuss with your doctors and tell them feedback about this medicine.

There is no specific information about whether this medicine is passed on to the baby through breast milk. Discuss with your doctor before breastfeeding.

Pack Size & Price